Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 2 of the last 2 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 2 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
DOCA-PHARMA from Sint-Niklaas, company number BE1013386219, closed financial year 2025 with a result of € -64,546 after tax. For that financial year DOCA-PHARMA recorded a gross margin of € -27,380 and equity of € -79,753. Compared with financial year 2024, the result moved from € -20,208 to € -64,546. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 24, 2026.
€ -79,753
▼ € 64,546 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -64,546
▼ 219 % more loss than in 2024
Profit after tax over the fiscal year.
€ 1,237
▼ 97% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -84,753.
People and assets in 2025
€ 24,104
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 35,301
▼ 18% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 140,000
▲ 40% vs 2024
€ 50,000 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.
€ 1,696
▲ 109% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 4,696
▲ € 4,111 vs 2024
Taxes, VAT and social contributions still to pay.
| 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|
| Gross margin | € -18,752 | € -27,380 | ▼ € 8,628 |
| Profit after taxes | € -20,208 | € -64,546 | ▼ € 44,338 |
| Equity | € -15,208 | € -79,753 | ▼ € 64,546 |
| Total debts | € 104,490 | € 152,137 | ▲ 46% |
| Cash | € 38,344 | € 1,237 | ▼ 97% |
| Retained profit | € -20,208 | € -84,753 | ▼ € 64,546 |
| Bank debt | € 100,000 | € 140,000 | ▲ 40% |
| Balance sheet total | € 89,282 | € 72,384 | ▼ 19% |
By gross margin, DOCA-PHARMA ranks 109th of 116 companies with main activity “Groothandel in farmaceutische en medische artikelen” in East Flanders that publish figures (fiscal year 2025).
Key figures of DOCA-PHARMA, fiscal years 2024 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
Ask about DOCA-PHARMA the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to DOCA-PHARMA?
What happened at DOCA-PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 64,546. Source: NBB ↗
- New establishment in Sint-Niklaas. KBO
- Start of the company according to the CBE. KBO
In short
From € 20,208 loss in 2024 to € 64,546 loss in 2025.
Management
Behind DOCA-PHARMA are Casper De Pryck and Domien Van Acker. Domien Van Acker is also behind DIERENARTS D.H.M. VAN ACKER.
Directors
According to the 2025 annual accounts
Casper De Pryck
Director
Establishments
Establishment units
Physical locations of this company
Edgar Tinelstraat 11
9112 Sint-Niklaas
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Similar companies in East Flanders
Same main activity (Groothandel in farmaceutische en medische artikelen), 196 active companies in East Flanders, largest first.
€ 1.8 billion revenue · 2025 · Sint-Niklaas
€ 278.3 million revenue · 2025 · Sint-Niklaas
€ 44.6 million revenue · 2025 · Gent
€ 35.3 million revenue · 2025 · Gent
€ 34.5 million revenue · 2024 · Gent
€ 32.9 million revenue · 2025 · Gent
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
HETZNER-AS, DE
Website info
Features
Security
Details
- Company number
- 1013.386.219
- VAT number
- BE 1013.386.219
- Registered office
- Edgar Tinelstraat 11, 9112 Sint-Niklaas
- Names & denominations
- DOCA-PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 10 September 2024
- Peppol
- Active · Active since 1 Jan 2001
- Contact
- doca-pharma.be
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Veterinaire diensten
Overige posterijen en koeriers
Overige zakelijke dienstverlening, neg